LEADER 03634nam 2200637 a 450 001 9910463229103321 005 20200520144314.0 010 $a0-313-39823-2 035 $a(CKB)2670000000339447 035 $a(StDuBDS)BDZ0021512897 035 $a(SSID)ssj0000834694 035 $a(PQKBManifestationID)12411137 035 $a(PQKBTitleCode)TC0000834694 035 $a(PQKBWorkID)10981851 035 $a(PQKB)11459646 035 $a(MiAaPQ)EBC1135400 035 $a(Au-PeEL)EBL1135400 035 $a(CaPaEBR)ebr10666594 035 $a(CaONFJC)MIL453615 035 $a(OCoLC)879022372 035 $a(EXLCZ)992670000000339447 100 $a20120724d2013 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aReproductive rights and the state$b[electronic resource] $egetting the birth control, RU-486, morning-after pills, and the Gardasil vaccine to the U.S. market /$fMelissa Haussman 210 $aSanta Barbara, Calif. $cPraeger$dc2013 215 $a1 online resource (184 p.) 225 0$aReproductive rights and policy 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-313-39822-4 320 $aIncludes bibliographical references and index. 327 $aIntroduction -- History of the FDA and drug regulation in the US -- The development of the pill -- U.S. pro-choice and pro-life groups' strategies since 1960 -- Problems with Mifepristone (RU 486) and Misoprostol (Cytotec), 1988-2000 -- The "Morning after pill," Plan B levonorgestrel formulation -- Reverse lobbying for Gardasil -- Conclusion--why a feminist historical institutionalist lens is important. 330 8 $aReproductive Rights and the State: Getting the Birth Control, RU-486, and Morning-After Pills and the Gardasil Vaccine to the U.S. Market tackles a subject that remains controversial more than 60 years after "e;the pill"e; was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market.To make her case, Melissa Haussman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S. government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits. 606 $aReproductive rights$zUnited States 606 $aBirth control$xGovernment policy$zUnited States 606 $aBirth control$xLaw and legislation$zUnited States 606 $aContraceptives$zUnited States 606 $aWomen's rights$zUnited States 608 $aElectronic books. 615 0$aReproductive rights 615 0$aBirth control$xGovernment policy 615 0$aBirth control$xLaw and legislation 615 0$aContraceptives 615 0$aWomen's rights 676 $a363.9/60973 700 $aHaussman$b Melissa$f1959-$0865266 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910463229103321 996 $aReproductive rights and the state$91931191 997 $aUNINA